Q-omics provides the consensus-scored C10orf120 profile across patient tissues and cancer cell-line models. C10orf120 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, C10orf120 is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, C10orf120 RNA expression shows 6,557 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, LUSC, and STAD as cancer lineages where C10orf120 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C10orf120 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C10orf120 survival associations across molecular data types. C10orf120 RNA expression shows survival associations in the most cancer types (12), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C10orf120 RNA expression–survival associations across cancer types. High C10orf120 expression shows unfavorable associations in HNSC, KIRC, UCS, STAD and READ, but favorable associations in LGG. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify HNSC as the clearest survival context for C10orf120 RNA expression.
This table summarizes C10orf120 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for C10orf120. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C10orf120 shows lower tumor expression in ESCA and higher tumor expression in LUSC. The LUSC box plot shows higher C10orf120 RNA expression in tumor versus normal tissue (log2 FC = +0.058, t-test p = .038).
This table shows molecular features associated with C10orf120 in patient tissues and cancer cell lines. In patient samples, C10orf120 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, C10orf120 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
